Advertisement

Clinical pharmacology of amantadine and derivatives

  • J. D. Parkes
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Summary

Amantadine has a definite although minor place in the clinical management of parkinsonism. It is simple to administer, well tolerated by patients, with rapid if usually minor to moderate benefit rather than dramatic response, and with few serious adverse effects.

Keywords

Herpes Zoster Anticholinergic Drug Methyl Amine Minor Place Amantadine Hydrochloride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aoki FY, Stiver HG, Sitar DS, Boudreault A, Ogilvie R (1985) Prophylactic amantadine dose and plasma concentrations—effect relationships in healthy adults. Clin Pharmacol Ther 128: 128–136CrossRefGoogle Scholar
  2. Borison RL (1983) Amantadine in the management of extrapyramidal side effects. Clin Neuropharmacol 6 [Suppl] 1: S 57–63CrossRefGoogle Scholar
  3. Dallos V, Heathfield K, Stone P (1972) Use of amantadine in Parkinson’s disease. Result of a double-blind trial. Br Med J. 4: 24–26CrossRefGoogle Scholar
  4. Fasano VA, Urciuoli R, Broggi G (1970) Primo osservazioni sull’uso dell’amantadina per via endovenosa e dulla associazione dell’amantadina per via orale con farmaci anticolinergici e con levo-dopa nel trattamento della malattia di Parkinson. Minerva Med 61: 2895PubMedGoogle Scholar
  5. Fünfgeld EW (1970) Amantadin-Wirkung bei Parkinsonismus. Dtsch Med Wochenschr 95: 1834–1836PubMedCrossRefGoogle Scholar
  6. Greenburg J (1971) Treatment of parkinsonism with amantadine hydrochloride. Pennsylv Med 74: 54Google Scholar
  7. Hayden FG, Hoffman HE, Spyker DA (1983) Differences in side effects of amantadine hydrochloride and Amantadine hydrochloride relative to differences in pharmacokinetics. Antimicrob Agents Chemother 23: 458–464PubMedGoogle Scholar
  8. Hunter KR, Stern GM, Laurence DR, Armitage P (1970) Amantadine in parkinsonism. Lancet i: 1127–1129CrossRefGoogle Scholar
  9. Kelly JT, Abazzahab FS (1971) The antiparkinsonian properties of amantadine in drug-induced parkinsonism. J Clin Pharmacol 11: 211Google Scholar
  10. McEvoy JP (1987) A double-blind crossover comparison of antiparkinsonian drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J Clin Psychiatr 48 [Suppl]: 20–23Google Scholar
  11. Mann DC, Pearce LA, Waterbury LD (1971) Amantadine for Parkinson’s disease. Neurology 21: 958–962PubMedGoogle Scholar
  12. Mindham RHS, Gaind R, Anstree BH, Rimmer L (1972) Comparison of amantadine, orphenadrine and placebo in the control of phenothiazineinduced parkinsonism. Psychol Med 2: 406PubMedCrossRefGoogle Scholar
  13. Parkes JD, Baxter RCH, Curzon G, Knill-Jones RP, Knott PJ, Marsden CD, Tattersall R, Vollum B (1971) Treatment of Parkinson’s disease with amantadine and levodopa. Lancet i: 1083–1085CrossRefGoogle Scholar
  14. Parkes JD, Baxter RB, Marsden CD, Rees JE (1974) Comparative study of amantadine, benzhexol and levodopa in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatr 37: 422–426PubMedCrossRefGoogle Scholar
  15. Parkes JD, Zilkha KJ, Calver DM, Knill-Jones RP (1970) Controlled trial of amantadine hydrochloride in Parkinson’s disease. Lancet i: 259–262CrossRefGoogle Scholar
  16. Schwab RS, England AC, Poskanzer DC, Young RR (1969) Amantadine in the treatment of Parkinson’s disease. J Am Med Ass 208: 1168CrossRefGoogle Scholar
  17. Stetter H (1954) Die Chemie der organischen Ringsbetreme mit Utotropin-Struktur. Angew Chem 66: 217CrossRefGoogle Scholar
  18. Timberlake WH, Vance MA (1978) Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann Neurol 3: 119–128PubMedCrossRefGoogle Scholar
  19. Völler G (1972) Zur Therapie des Parkinson-Syndroms mit Amantadin. Munch Med Wochenschr 14: 1066Google Scholar
  20. Webster DD, Sawjer GT (1984) The combined use of amantadine HCI and levodopa/carbidopa in Parkinson’s disease. Curr Ther Res 35: 1010–1013Google Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • J. D. Parkes
    • 1
  1. 1.Department of Neurology, Institute of PsychiatryKing’s College School of Medicine and DentistryLondonUK

Personalised recommendations